Efficacy of conventional synthetic disease-modifying antirheumatic drugs, glucocorticoids and tofacitinib: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis
Addition of low-dose glucocorticoids to csDMARD therapy produces benefits in early RA. Under tight control conditions, combination therapy with csDMARDs is no better than MTX monotherapy. Tofacitinib is a new DMARD with proven efficacy.
|
|
Authors: Gaujoux-Viala, C.; Nam, J.; Ramiro, S.; Landewe, R.; Buch, M. H.; Smolen, J. S.; Gossec, L. Title: Efficacy of conventional synthetic disease-modifying antirheumatic drugs, glucocorticoids and tofacitinib: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis Year: 2014 Journal: Ann Rheum Dis Volume: 73 Issue: 3 Pages: 510-5 Pubmed Link: Click here. |